Literature DB >> 23311757

The genetics of Canadian type 3 von Willebrand disease: further evidence for co-dominant inheritance of mutant alleles.

M Bowman1, A Tuttle, C Notley, C Brown, S Tinlin, M Deforest, J Leggo, V S Blanchette, D Lillicrap, P James.   

Abstract

BACKGROUND: Type 3 von Willebrand disease (VWD) is the most severe form of the disease and is classically inherited in an autosomal recessive fashion.
OBJECTIVES: The aim of the current study was to investigate the molecular pathogenesis of a Canadian cohort of type 3 VWD patients. PATIENTS AND METHODS: Thirty-four families comprised of 100 individuals were investigated. Phenotypic data, including bleeding scores (BS), von Willebrand factor (VWF) laboratory values and anti-VWF inhibitor status were included as well as sequence analysis.
RESULTS: We identified 31 different mutations (20 novel): 8 frameshift, 5 splice site, 9 nonsense, 1 gene conversion, 6 missense and 2 partial gene deletion mutations. The majority of mutations identified were in the propeptide (42%); index cases (IC) with these mutations exhibited more severe bleeding (BS = 22) than those with mutations elsewhere in VWF (BS = 13). Sixty-two out of 68 (91%) mutant alleles were identified. Twenty-nine IC (85%) had a VWF null genotype identified; 17 homozygous, 12 compound heterozygous. In five IC (15%), two mutant VWF alleles were not identified to explain the type 3 VWD phenotype. In four ICs only one mutant VWF allele was identified and in one IC no mutant VWF alleles were identified.
CONCLUSIONS: We have investigated the molecular pathogenesis of a Canadian cohort of type 3 VWD patients. Obligate carriers are not phenotypically silent in the Canadian population; 48% have been diagnosed with type 1 VWD. In approximately 50% of families in this study the inheritance pattern for type 3 VWD is co-dominant and not recessive.
© 2013 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23311757      PMCID: PMC3904644          DOI: 10.1111/jth.12130

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  37 in total

1.  A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies.

Authors:  D K Lahiri; J I Nurnberger
Journal:  Nucleic Acids Res       Date:  1991-10-11       Impact factor: 16.971

Review 2.  Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology.

Authors:  J C Eikenboom
Journal:  Best Pract Res Clin Haematol       Date:  2001-06       Impact factor: 3.020

3.  Gene deletions correlate with the development of alloantibodies in von Willebrand disease.

Authors:  B B Shelton-Inloes; F F Chehab; P M Mannucci; A B Federici; J E Sadler
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

4.  Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients.

Authors:  Luciano Baronciani; Giovanna Cozzi; Maria Teresa Canciani; Flora Peyvandi; Alok Srivastava; Augusto B Federici; Pier Mannuccio Mannucci
Journal:  Blood Cells Mol Dis       Date:  2003 May-Jun       Impact factor: 3.039

5.  Severe type III von Willebrand's disease caused by deletion of exon 42 of the von Willebrand factor gene: family studies that identify carriers of the condition and a compound heterozygous individual.

Authors:  I R Peake; M B Liddell; P Moodie; G Standen; D J Mancuso; E A Tuley; L A Westfield; J M Sorace; J E Sadler; C L Verweij
Journal:  Blood       Date:  1990-02-01       Impact factor: 22.113

6.  Mutations of von Willebrand factor gene in families with von Willebrand disease in the Aland Islands.

Authors:  Z P Zhang; M Blombäck; D Nyman; M Anvret
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

7.  Characterization of the von Willebrand factor gene (VWF) in von Willebrand disease type III patients from 24 families of Swedish and Finnish origin.

Authors:  Z P Zhang; M Blombäck; N Egberg; G Falk; M Anvret
Journal:  Genomics       Date:  1994-05-01       Impact factor: 5.736

8.  Genetic heterogeneity of severe von Willebrand disease type III in the German population.

Authors:  R Schneppenheim; S Krey; F Bergmann; D Bock; U Budde; M Lange; R Linde; U Mittler; E Meili; G Mertes
Journal:  Hum Genet       Date:  1994-12       Impact factor: 4.132

9.  Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease.

Authors:  K Y Ngo; V T Glotz; J A Koziol; D C Lynch; J Gitschier; P Ranieri; N Ciavarella; Z M Ruggeri; T S Zimmerman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

10.  Nonsense mutations of the von Willebrand factor gene in patients with von Willebrand disease type III and type I.

Authors:  Z P Zhang; M Lindstedt; G Falk; M Blombäck; N Egberg; M Anvret
Journal:  Am J Hum Genet       Date:  1992-10       Impact factor: 11.025

View more
  24 in total

1.  Translational medicine advances in von Willebrand disease.

Authors:  D Lillicrap
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

2.  Characterization of large in-frame von Willebrand factor deletions highlights differing pathogenic mechanisms.

Authors:  Ashley Cartwright; Simon J Webster; Annika de Jong; Richard J Dirven; Lisa D S Bloomer; Ahlam M Al-Buhairan; Ulrich Budde; Christer Halldén; David Habart; Jenny Goudemand; Ian R Peake; Jeroen C J Eikenboom; Anne C Goodeve; Daniel J Hampshire
Journal:  Blood Adv       Date:  2020-07-14

Review 3.  Laboratory aspects of von Willebrand disease: test repertoire and options for activity assays and genetic analysis.

Authors:  G Castaman; A Hillarp; A Goodeve
Journal:  Haemophilia       Date:  2014-05       Impact factor: 4.287

4.  The role of genetics in the pathogenesis and diagnosis of type 1 Von Willebrand disease.

Authors:  Veronica H Flood; Jessica Garcia; Sandra L Haberichter
Journal:  Curr Opin Hematol       Date:  2019-09       Impact factor: 3.284

Review 5.  Angiodysplasia in von Willebrand Disease: Understanding the Clinical and Basic Science.

Authors:  Soundarya Selvam; Paula James
Journal:  Semin Thromb Hemost       Date:  2017-05-05       Impact factor: 4.180

6.  Von Willebrand factor regulates complement on endothelial cells.

Authors:  Damien G Noone; Magdalena Riedl; Fred G Pluthero; Mackenzie L Bowman; M Kathryn Liszewski; Lily Lu; Yi Quan; Steve Balgobin; Reinhard Schneppenheim; Sonja Schneppenheim; Ulrich Budde; Paula James; John P Atkinson; Nades Palaniyar; Walter H A Kahr; Christoph Licht
Journal:  Kidney Int       Date:  2016-05-25       Impact factor: 10.612

Review 7.  New insights into genotype and phenotype of VWD.

Authors:  Veronica H Flood
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2014-11-18

Review 8.  Diagnosing von Willebrand disease: genetic analysis.

Authors:  Anne Goodeve
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 9.  von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.

Authors:  David Lillicrap
Journal:  Blood       Date:  2013-09-24       Impact factor: 22.113

Review 10.  Genetic regulation of plasma von Willebrand factor levels in health and disease.

Authors:  L L Swystun; D Lillicrap
Journal:  J Thromb Haemost       Date:  2018-10-30       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.